Architectural Heterogeneity in Tumors Caused by Differentiation
Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound
Figure 3
(a) Bar graphs show MVD counts per high-power field (HPF) (original magnification, 400) in the untreated versus MSC-treated xenografts and surgical samples following 14 days of MSC treatment (0.2 mg/mouse/day). Significant reduction in MVD was seen in A253 and H69 xenografts after 14 days of MSC treatment with no changes seen in A549 xenografts or the surgical samples. (b) MSC led to an improved vascular maturation in A253, H69, A549 xenografts and PDSCC but did not induce any change in WDSCC and normal liver. (c) Treatment with MSC (0.2 mg/mouse/day 14) led to a lowering of interstitial fluid pressure in A253 but not in H69 and A549 xenografts. (d) As a consequence, there was a significant improvement in tumor doxorubicin fluorescence intensity gradient in A253 xenografts but not in H69 or A549 xenografts. (e) MSC did not result in an improvement in tumor doxorubicin fluorescence intensity gradient in the surgical samples PDSCC and WDSCC.
